Lactobacillus gasseri CP2305 is a strain of lactic acid bacteria isolated from the stool of a healthy adult. Six of its 7 trials in PubMed used heat-treated cells, which are not alive. Trial reports call such cells a paraprobiotic or a postbiotic. Trials state the amount as a count of cells; most used 10 billion a day.
Terms and sources
- isolated
- Sugawara et al., Microb Ecol Health Dis, 2016; Nishida et al., Nutrients, 2019.
- heat-treated cells
- Grown, washed with water, heated to 90 °C (194 °F) and freeze-dried. Sugawara et al., 2016. The seventh trial, in people with a diagnosis, used live cells, by the account of Nishida et al., 2019.
- postbiotic
- NIH ODS uses the word postbiotics for preparations of dead microorganisms; see below.
- 10 billion
- 1 × 10¹⁰ cells, as two tablets or one 200 mL drink. Tanihiro et al., 2026, state that earlier trials used this amount consistently.
Heat-treated CP2305 in the body
Heat-treated CP2305 is not a nutrient, and the body has no daily requirement for it. Its trials measure sleep questionnaires, sleep by home EEG, stress ratings and stool habits.
One trial report states that heat-treated CP2305 cannot survive in the gut or make active metabolites. Another states that the trial tablets hold no active metabolites made by live bacteria. Live CP2305 was reported to settle in the gut of 40% of people who took it.
Terms and sources
- cannot survive in the gut
- Tanihiro et al., Frontiers in Nutrition, 2026. All 4 authors worked at Asahi Quality and Innovations, Ltd.
- Another states
- Nishida et al., Nutrients, 2019.
- 40% of people
- Nishida et al., 2019, citing earlier work. The figure is for live cells, not heat-treated ones.
NIH ODS separates probiotics from postbiotics: "Probiotics should also not be confused with postbiotics, which are preparations comprised of dead, intact, or fragmented microorganisms, with or without their metabolites, that confer a health benefit on the host." NCCIH describes probiotics as live microorganisms. NIH ODS quotes a definition from ISAPP that also calls them live. We found no text from either agency on heat-treated CP2305. Their safety sections are about probiotics as defined above; they do not mention heat-treated cells. The 2 trials listed below report no adverse events.
Terms and sources
- separates probiotics from postbiotics
- NIH Office of Dietary Supplements, probiotics fact sheet for health professionals. It cites the 2021 consensus statement of the International Scientific Association for Probiotics and Prebiotics.
- live microorganisms
- NCCIH, Probiotics: Usefulness and Safety.
- ISAPP
- International Scientific Association for Probiotics and Prebiotics. NIH ODS, probiotics fact sheet for health professionals.
- no adverse events
- Nishida 2019: 60 students over 24 weeks. Tanihiro 2026: 28 adults after one dose.
Where CP2305 comes from
For one trial, the strain was grown in a broth of glucose, casein, fish peptone and yeast extract. The cells were then filtered, washed with water, heated to 90 °C (194 °F) and freeze-dried. Another trial report gives at least 760 billion cells per gram of the dried powder. By our calculation, 10 billion cells come to about 13 mg of that powder or less.
Terms and sources
- For one trial
- Sugawara et al., Microb Ecol Health Dis, 2016. The broth also held a pH adjuster and an emulsifier.
- heated to 90 °C (194 °F)
- Sugawara et al., 2016.
- at least 760 billion cells per gram
- 7.6 × 10¹¹ cells per gram. Fuchida et al., Toxicology Reports, 2026.
- about 13 mg
- 10 billion ÷ 760 billion per gram = 0.013 g. Our estimate; the powder has at least that many cells per gram.
The trial tablets also hold maltose, dextrin, starch and vegetable oil. The dummy tablets replace the cell powder with dextrin. A trial drink with the cells was made at Asahi Soft Drinks Co., Ltd.
Terms and sources
- maltose, dextrin, starch and vegetable oil
- Nishida et al., 2019; Tanihiro et al., 2026.
- Asahi Soft Drinks Co., Ltd.
- Sugawara et al., 2016.
Published studies of CP2305
We found no text from NIH ODS or NCCIH that rates the evidence for CP2305. All 7 trial reports of CP2305 we found in PubMed list an author from an Asahi Group company.
Terms and sources
- an Asahi Group company
- Asahi Group Holdings, Ltd., or Asahi Quality and Innovations, Ltd., by PubMed affiliations. Five of these reports state that an Asahi company paid for the study. We could not read the funding sections of the other 2.
Trials in people with a diagnosis, or chosen by symptom scores or bowel habits, are not listed here.
2 studies in adults without a diagnosis: 2 found a difference.
Both listed trials used 10 billion heat-treated cells. Asahi Group Holdings paid for both. Not listed: a review that combined trials, whose trial list we could not read. Also not listed: a trial whose abstract does not state random groups or a comparison. Also not listed: trials that chose people by symptom scores or by bowel habits. Also not listed: a trial of 100 billion cells a day. Also not listed: a trial in people with a diagnosis, which used live cells. Also not listed: a review of many preparations that its authors call postbiotics.
Our one-line summary comes first. The original is on PubMed.
Show the 2 studies
Medical students preparing for a national exam took CP2305 tablets for 24 weeks; sleep scores differed from a dummy tablet.
Trial · 60 people · 24 weeks · industry-funded
Nishida et al., Nutrients, 2019
Terms and sources
- Medical students
- 60 sixth-year medical students in Japan, 41 men and 19 women. None had a diagnosed illness or took regular medicines. The methods and results give different group splits, 29 and 31 or 31 and 29. 74 were recruited. The paper lists 7 excluded for medicines, 3 for hormonal contraceptives and 4 for active illness.
- national exam
- The 24 weeks ended 2 weeks before the national medical licensing exam. Students were not chosen by symptom scores.
- CP2305 tablets
- Two tablets once a day, with 10 billion heat-inactivated, washed and dried CP2305 cells. The authors report no adverse events.
- sleep scores
- Sleep questionnaire (PSQI) scores differed from the dummy tablet. By home EEG, time to the first deep-sleep stage and time awake after falling asleep were shorter. Total REM and non-REM sleep did not differ. The share of deep-sleep brain waves in the first sleep cycle was higher than with the dummy tablet. Total deep-sleep wave power did not differ.
- differed
- Statistically significant. Usual-tension scores, a hospital mood questionnaire, irritability and stomach discomfort ratings and saliva chromogranin A also differed. Current-tension scores rose before the exam in both groups and did not differ. Saliva cortisol did not differ. General health questionnaire totals did not differ; one of its subscales did. Weekly tiredness and sleep-trouble ratings were collected; the paper gives no result for them.
- a dummy tablet
- Placebo tablets made the same way, with dextrin in place of the cell powder.
- industry-funded
- Asahi Group Holdings, Ltd. paid for the study. One of 5 authors works at Asahi Quality & Innovations, Ltd., a related company.
Study · Free full text · about 21 min to read
Our estimate at 200 words a minute, from the words of the abstract and main text without tables and figures.
Study summary
Sixty medical students in Japan took tablets with 10 billion heat-inactivated CP2305 cells or a dummy tablet for 24 weeks. The trial ended 2 weeks before their national exam. Sleep questionnaire scores differed from the dummy tablet. By home EEG, time to deep sleep and time awake at night were shorter. Usual-tension and mood scores also differed. Current-tension scores rose in both groups before the exam and did not differ. Saliva cortisol did not differ. The authors report no adverse events. Funding: Asahi Group Holdings. One author works at Asahi Quality & Innovations, a related company.
Healthy adults took one dose of CP2305 tablets; stress ratings and some brain-wave measures differed from a dummy tablet.
Trial · 28 people · One dose, each tablet type · industry-funded
Tanihiro et al., Frontiers in Nutrition, 2026
Terms and sources
- Healthy adults
- 28 healthy adults aged 20–44, 14 women and 14 men. The authors report no adverse events or side effects.
- one dose
- Each took both tablet types, one after the other, at least 3 days apart, in random order.
- CP2305 tablets
- Two tablets with 10 billion heat-treated CP2305 cells.
- stress ratings
- Measured after mental arithmetic and a listening attention task, within 60 minutes. A 0–100 mm stress scale and the tension score of a mood questionnaire differed from the dummy tablet. The other 6 mood scores did not.
- some brain-wave measures
- Alpha power rose more than with the dummy tablet at 4 of 8 scalp sites. It did not differ at the other 4. Beta power differed at 1 site. Pulse-interval variation (RMSSD) during the arithmetic task also differed. The authors read it as rest-and-digest nerve activity. EEG data from 23 people (22 in the dummy-tablet condition) and pulse data from 24 were analyzed.
- a dummy tablet
- Placebo tablets with dextrin in place of the cell powder, the same in look and taste.
- industry-funded
- Asahi Group Holdings, Ltd. paid for the study. All 4 authors worked at Asahi Quality and Innovations, Ltd., a group affiliate.
Study · Free full text · about 29 min to read
Our estimate at 200 words a minute, from the words of the abstract and main text without tables and figures.
Study summary
Twenty-eight healthy adults took tablets with 10 billion heat-treated CP2305 cells once and a dummy tablet once, in random order. After mental arithmetic and a listening task, stress ratings differed from the dummy tablet. So did the tension score of a mood questionnaire. Six other mood scores did not differ. Alpha brain waves rose more at 4 of 8 scalp sites. Pulse-interval variation also differed. The authors report no adverse events. Funding: Asahi Group Holdings. All 4 authors worked at its affiliate Asahi Quality and Innovations.
Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.